Prospect News: News for Incyte Corp.

E-mail us: service@prospectnews.com Or call: 212 374 2800

Bank Loans - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products

Add to balance / Manage account

Not logged in

Prospect News home > Main news index > All issuers starting with I > Issuers starting with I, CV only > All stories on Incyte Corp. > Stories on Incyte Corp., CV only

Search again

Enter part or all of the issuer name:

Market:

All markets No structured products Bank loans Canadian bonds CLOs Convertibles Distressed debt Emerging markets High yield Investment grade Liability management Municipals PIPEs Preferreds Private placements All leveraged markets Structured products

Market: BK = Bank loans, CV = Convertibles, DD = Distressed Debt, EM = Emerging Markets, HY = High Yield, IG = Investment Grade, LM = Liability Management, MU = Municipals, PP = PIPEs, PF = Preferreds, PV = Private Placements, SP = Structured Products
Recent items, highlighted in orange, are $4.00 each. All others are $1.00 each. Headlines in gray are not currently covered by your subscription.

Incyte Corp.

2/21/2017	CVLM	Incyte agrees to exchange some 0.375% convertibles, 1.25% convertibles
8/22/2016	CV	Market Commentary: Biotech names eyed after Medivation takeout news; BioMarin convertibles add with shares
1/11/2016	CV	Market Commentary: Energy-related convertibles move lower; other sectors hold in on swap; Depomed drops
1/11/2016	CV	Market Commentary: Morning Commentary: Depomed convertibles, shares lower; health care in focus during conference
2/12/2015	CV	Market Commentary: Tesla drops outright, narrowly mixed on hedge after disappointing earnings; Nvidia expands
11/14/2013	CV	Incyte greenshoe lifts two-part convertibles deal to $750 million
11/8/2013	CV	Market Commentary: Midday Commentary: Incyte's two-tranche deal prices, trades up; MolyCorp falls on earnings
11/8/2013	CV	New Issue: Incyte sells $700 million of convertible senior notes in two tranches
11/8/2013	CV	Market Commentary: Incyte's $700 million two-tranche deal prices, trades up; Molycorp falls on wider loss
11/7/2013	CV	Market Commentary: ServiceNow holds up on debut; InvenSense adds; planned Incyte looks cheap; earnings eyed
11/6/2013	CV	Incyte to price $700 million of convertible senior notes in two parts
11/6/2013	CV	Market Commentary: New Layne Christensen holds up on debut; planned ServiceNow looks cheap; Incyte on tap
9/17/2013	CVLM	Incyte exchanges $37.29 million 4.75% convertibles for stock, cash
6/5/2013	CVLM	Incyte agrees to exchange $37.46 million 4.75% convertibles due 2015
5/3/2011	CV	Market Commentary: Mylan off outright, expands on hedge; Incyte premium comes in; Alaska Communications on tap
9/13/2010	CV	Market Commentary: Hertz comes 'in' a little on swap with better Dollar Thrifty bid; Level 3, Volcano on tap
8/2/2010	CV	Market Commentary: Newell Rubbermaid adds more than 2 points of premium; Teleflex plans $350 million deal
4/23/2010	CV	Market Commentary: Health care names recover; investment-grade names in focus; Incyte, Textron strengthen
2/23/2010	CV	Incyte holders convert $16.9 million 3.5% notes ahead of redemption
2/1/2010	CV	Market Commentary: Convertibles firmer; USEC better on Obama comments; Newmont Mining in trade as gold gains
1/28/2010	CV	Incyte to redeem all of its 3.5% convertibles due 2011 on Feb. 22
1/15/2010	CV	Market Commentary: SanDisk, Bunge up on yield trades; Micron Technology slips with stock; Incyte down, active
11/5/2009	CV	Incyte retires $212.3 million of two series of 3.5% convertible notes
11/5/2009	CV	Market Commentary: Ford active, weaker after debut; Jakks Pacific trades over par; MasTec quiet; Incyte gains
11/2/2009	CV	Market Commentary: YRC jumps on exchange; Vornado up on tender; Human Genome surges on lupus drug; Ford to price
10/6/2009	CV	Market Commentary: MannKind drops on partnership deal delay; Medtronic, Transocean gain; Avis, AirTran plan deals
10/5/2009	CV	Market Commentary: UAL adds amid quiet trading; AMD gains; Medtronic up in solid volume; trading breadth narrow
9/30/2009	CV	Incyte buys back $186.2 million in two series of 3.5% convertibles
9/30/2009	CV	Incyte greenshoe exercised, raising convertibles to $400 million
9/25/2009	CV	Market Commentary: Incyte trades up smartly on debut; AMR steady to stronger; Gaylord, PHH tracking over par
9/24/2009	CV	New Issue: Incyte prices upsized $350 million of six-year convertibles to yield 4.75%, up 30%
9/24/2009	CV	Market Commentary: Gaylord, PHH, ATP Oil slip from highs with stocks; Incyte looks less cheap as terms reset
9/23/2009	CV	Market Commentary: AMR, Goodrich Petroleum gain on debuts; Gaylord Entertainment, PHH price upsized deals
9/22/2009	CV	Incyte to price $250 million six-year convertible notes to yield 5%-5.5%, up 22.5%-27.5%
9/22/2009	CV	Market Commentary: AMR adds in gray, then upsizes; MannKind gains more: Goodrich, ATP, Incyte, Gaylord to price
9/22/2009	CV	Incyte plans to retire two series of 3.5% convertibles due 2011
3/6/2009	CVHY	Incyte files $150 million shelf
9/26/2006	BTCV	Incyte greenshoe exercised, upping convertibles to $151.8 million
9/26/2006	BTCV	Incyte calls 5.5% convertibles due 2007
9/21/2006	CV	Market Commentary: Incyte's new notes rise as old paper crumples; Priceline deal seen as rich; Novell gains on default potential
9/21/2006	BTCV	New Issue: Incyte reoffers $132 million 4.4-year 3.5%, up 126.2% convertibles within talk, at 78
9/20/2006	CV	Market Commentary: First Industrial, BioMed higher on debuts; XM gains further; Red Hat climbs with stock; Incyte plans deal
9/20/2006	BTCV	New Issue: Incyte to offer $132 million 4.4-year, 3.5%, up 126.2% convertibles at discounted 77-79
9/20/2006	BTCV	Incyte to call 5.5% convertibles due 2007
4/6/2006	CV	Market Commentary: Allergan new deal stumbles in the gray; Annaly offering seen as hedge play; Cell Therapeutics plans deal
11/21/2005	CV	Market Commentary: GM mixed in light trade, Ford flat, Incyte gains on Pfizer pact, but SFBC falls
11/1/2005	BTCV	Incyte pays $35.8 million to buy back 5.5% convertibles
9/28/2005	CV	Market Commentary: Euronet prices upsized deal, TriZetto on deck; new US Airways' convertible gains; Incyte tumbles
8/1/2005	CV	Incyte spends $28.4 million to buy back convertibles
5/11/2005	CV	Market Commentary: Delta bankruptcy seen inevitable; GM, Ford weigh financials, IPG; KV Pharma slammed; Red Hat up
11/4/2004	CV	Incyte buys back $38.4 million 5.5% convertibles
4/27/2004	CV	Market Commentary: Reebok bounces to 102.25; OSI Pharma, cancer issues snap back; three deals at bat
3/8/2004	CV	Incyte greenshoe exercised, raising convertibles to $250 million
2/13/2004	CV	New Issue: Incyte upsized $200 million convertible yields 3.5%, up 35%
2/13/2004	CV	Market Commentary: Adelphia bonds Earthbound, lose 6 points; Sirius, new paper active but slip to below par levels
2/12/2004	CV	Incyte prices upsized $200 million convertibles to yield 31/2%, up 35%
2/12/2004	CV	Market Commentary: Buyers propel new AMR convert; Bristol-Myers up on Erbitux news; Incyte trades at par in gray market
2/11/2004	CV	Incyte $150 million convertible talked at 3.25-3.75% yield, up 32.5-37.5%
2/11/2004	CV	Market Commentary: Disney steals show; Echostar cast as takeover target, too; Safeguard advanced
11/10/2003	CV	Market Commentary: Biotech paper grabs attention as yield-hungry investors invade market

©2025 Prospect News. This page is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies, faxing, photocopying or any other form of reproduction.